ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02 — DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

(a) Not applicable.

(b) Howard H. Pien, a director of ImmunoGen,Inc. (the “Company”), resigned from the Board of Directors, effective January19, 2018.

(c) Not applicable.

(d) On January23, 2018, the Board elected Stuart Arbuckle as a director to fill the vacancy created by Mr.Pien’s resignation from the Board. Mr.Arbuckle will also serve as a member of the Governance and Nominating Committee of the Board of Directors.

A description of the compensation payable to Mr.Arbuckle for his service as a director is set forth in the Company’s definitive Proxy Statement dated April28, 2017, filed with the Securities and Exchange Commission on April28, 2017, under the caption “Director Compensation,” and is incorporated herein by reference.

(e) Not applicable.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d): The following exhibit is being furnished herewith:


IMMUNOGEN INC Exhibit
EX-99.1 2 a18-3664_1ex99d1.htm EX-99.1 Exhibit 99.1     ImmunoGen Appoints Stuart A. Arbuckle to Board of Directors   WALTHAM,…
To view the full exhibit click here

About ImmunoGen,Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.